ArticleScientific reports2025
Clinical significance of FOXN3 expression in Indian breast cancer patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, breast cancer is the most common cancer to affect women. There are different molecular and pathological factors that are involved in the uncontrolled proliferation of breast cancer cells. FOXN3 that is member of Forkhead box family proteins is well recognized for having a crucial role in different biological processes and is reported to be dysregulated in various malignancies. The studies to evaluate the significance of the FOXN3 gene in progression of breast cancer are still under progress. We in the current study aim to examine the FOXN3 gene expression in Indian breast cancer patients and find its clinical relevance. FOXN3 expression analysis using RT-PCR, immunohistochemistry, and western blotting was performed in tumor and normal tissue collected from 142 sporadic breast cancer patients. To identify the genetic aberrations in FOXN3 gene automated DNA sequencing was done. FOXN3 expression study revealed the elevated expression of FOXN3 mRNA in 61.26% of the cases whereas FOXN3 protein was seen to be overexpressed in 59.15% cases. Further, it was found that the elevated expression of FOXN3 mRNA was significantly correlated with the post-menopausal (p = 0.003) status and positive lymph node status (p = 0.049) of the patients. The FOXN3 protein expression also exhibited the significant association with menopausal status (p = 0.008), lymph node status (p = 0.001) and clinical stage (p = 0.018) of the patients. However, we did not find any mutation in the DNA binding domain of the FOXN3 gene in the Indian breast cancer cases. Our findings indicates that overexpression of FOXN3 gene in Indian breast cancer cases can have a potential role in breast cancer progression especially in advanced clinical stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.